All > Lynch Syndrome > Endometrial Cancer

Tegavivint for Wilms Tumor

Phase-Based Progress Estimates

Effectiveness

Safety

Wilms Tumor+36 More

Tegavivint - Drug

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

< 65

All Sexes

What conditions do you have?

Select

Eligibility

< 65

All Sexes

What conditions do you have?

Select

Study Summary

This trial is testing a new drug to see if it can stop the growth of cancer cells.

Eligible Conditions

Wilms Tumor
Colorectal Carcinoma
Ovarian Carcinoma
Refractory Osteosarcoma
Endometrial Carcinoma
Melanoma
recurrent Ewing's Sarcoma
Hepatoblastoma
Liver carcinoma
Lymphoma, Non-Hodgkin
Osteosarcoma
Fibromatosis, Aggressive
Refractory Ewing Sarcoma
Pancreas
Neuroblastoma
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Recurrent Malignant Solid Neoplasm
Refractory Hepatoblastoma
Refractory Hepatocellular Carcinoma
Malignant Neoplasms

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Wilms Tumor

Ipilimumab

Magnetic Resonance High Intensity Focused Ultrasound

second generation 4-1BBζ EGFR806-EGFRt

Study Objectives

8 Primary · 1 Secondary · Reporting Duration: Up to 60 months

Up to 2 days

Area under the drug concentration curve of tegavivint

Clearance of tegavivint

Half-life of tegavivint

Maximum serum concentration of tegavivint

Minimum serum concentration of tegavivint

Up to 28 days

Frequency of dose limiting toxicities of tegavivint

Up to 336 days

Antitumor effects of tegavivint in patients with solid tumors

Up to 60 days

Antitumor effect of tegavivint

Up to 60 months

Frequency of adverse events attributable to tegavivint

Trial Safety

Safety Progress

1 of 3

Other trials for Wilms Tumor

Ipilimumab

Magnetic Resonance High Intensity Focused Ultrasound

second generation 4-1BBζ EGFR806-EGFRt

Trial Design

1 Treatment Group

Treatment (tegavivint)

1 of 1

Experimental Treatment

147 Total Participants · 1 Treatment Group

Primary Treatment: Tegavivint · No Placebo Group · Phase 1 & 2

Treatment (tegavivint)Experimental Group · 3 Interventions: X-Ray Imaging, Dual X-ray Absorptiometry, Tegavivint · Intervention Types: Procedure, Procedure, Drug

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dual X-ray Absorptiometry

2019

N/A

~30

Tegavivint

2018

Completed Phase 1

~30

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: up to 60 months

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor

446 Previous Clinical Trials

234,943 Total Patients Enrolled

29 Trials studying Wilms Tumor

17,879 Patients Enrolled for Wilms Tumor

National Cancer Institute (NCI)NIH

12,991 Previous Clinical Trials

41,298,346 Total Patients Enrolled

54 Trials studying Wilms Tumor

21,409 Patients Enrolled for Wilms Tumor

Sarah B WhittlePrincipal InvestigatorPediatric Early Phase Clinical Trial Network

Eligibility Criteria

Age < 65 · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

Patients with recurrent or refractory solid tumors including non-Hodgkin lymphoma and desmoid tumors are eligible

You have a solid tumor that has relapsed or has not responded to treatment.

You have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment

About The Reviewer

Michael Gill - B. Sc.

First Published: October 19th, 2021

Last Reviewed: October 10th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References